机构:
Univ Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
OncoTeam Diagnost SA, Dept Mol Biol, 371 Grivitei Ave,Sect 1, Bucharest 010719, RomaniaUniv Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
Zamfir, Maria-Anca Irofei
[1
,2
]
Buburuzan, Laura
论文数: 0引用数: 0
h-index: 0
机构:
OncoTeam Diagnost SA, Dept Mol Biol, 371 Grivitei Ave,Sect 1, Bucharest 010719, RomaniaUniv Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
Buburuzan, Laura
[2
]
论文数: 引用数:
h-index:
机构:
Hudita, Ariana
[1
]
Galateanu, Bianca
论文数: 0引用数: 0
h-index: 0
机构:
Univ Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, RomaniaUniv Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
Galateanu, Bianca
[1
]
Ginghina, Octav
论文数: 0引用数: 0
h-index: 0
机构:
Carol Davila Univ Med & Pharm, Fac Med, Bucharest, RomaniaUniv Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
Ginghina, Octav
[3
]
Ion, Daniel
论文数: 0引用数: 0
h-index: 0
机构:
Carol Davila Univ Med & Pharm, Fac Med, Bucharest, RomaniaUniv Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
Ion, Daniel
[3
]
Motas, Natalia
论文数: 0引用数: 0
h-index: 0
机构:
OncoTeam Diagnost SA, Dept Mol Biol, 371 Grivitei Ave,Sect 1, Bucharest 010719, Romania
Carol Davila Univ Med & Pharm, Fac Med, Bucharest, RomaniaUniv Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
Motas, Natalia
[2
,3
]
Ardeleanu, Carmen Maria
论文数: 0引用数: 0
h-index: 0
机构:
OncoTeam Diagnost SA, Dept Mol Biol, 371 Grivitei Ave,Sect 1, Bucharest 010719, RomaniaUniv Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
Ardeleanu, Carmen Maria
[2
]
Costache, Marieta
论文数: 0引用数: 0
h-index: 0
机构:
Univ Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, RomaniaUniv Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
Costache, Marieta
[1
]
机构:
[1] Univ Bucharest, Fac Biol, Dept Biochem & Mol Biol, Bucharest, Romania
[2] OncoTeam Diagnost SA, Dept Mol Biol, 371 Grivitei Ave,Sect 1, Bucharest 010719, Romania
[3] Carol Davila Univ Med & Pharm, Fac Med, Bucharest, Romania
来源:
ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY
|
2022年
/
63卷
/
01期
Liquid biopsy is a promising tool for a better cancer management and currently opens perspectives for several clinical applications, such as detection of mutations when the analysis from tissue is not available, monitoring tumor mutational burden and prediction of targeted therapy response. These characteristics validate liquid biopsy analysis as a strong cancer biomarkers source with high potential for improving cancer patient's evolution. Compared to classical biopsy, liquid biopsy is a minimal invasive procedure, and it allows the real-time monitoring of treatment response. Considering that lung cancer is the most common cause of cancer-associated death worldwide and that only 15-19% of the lung cancer patients survive five years after diagnosis, there is an important interest in improving its management. Like in other types of solid cancers, lung cancer could benefit from liquid biopsy through a simple peripheral blood sample as tumor-related biomarkers, such as circulating tumor cells (CTCs), cell-free nucleic acids (cfNA) [cell-free ribonucleic acid (cfRNA) and cell-free deoxyribonucleic acid (cfDNA)], exosomes and tumor-educated platelets (TEPs) may shed into circulation because of necrosis or in an active manner. More, the detection and analysis of these biomarkers could lead to a better understanding of oncological diseases like lung cancer. The better the tumor profile is established; the better management is possible. However, this approach has currently some limitations, such as low cfNA concentration or low count of CTCs that might be overcome by improving the actual methods and technologies.